BIOMARKER RESEARCH: EXPLORE CUTTING-EDGE INSIGHTS WITH ANYGENES® SOLUTIONS

AnyGenes® was referenced in a recent article that investigates the clinical and molecular characteristics of long-term survivors (LS) of non-small cell lung cancer (NSCLC) who lack driver alterations. These survivors exhibit an overall survival rate exceeding three years. The study identifies key gene expression differences between long-term survivors (LS) and short-term survivors (SS), highlighting specific genes that are under-expressed in SS. The AnyGenes products used by the research team played a key role in these findings. To read the full article, visit: PubMed Article.

AnyGenes® is highlighted in the article titled "CircRNA circPTK2 May Inhibit Glioblastoma Cell Invasion and Migration by Targeting miR-23a Maturation," published on PubMed. This study explores the potential of circRNA circPTK2 in glioblastoma, a highly aggressive brain cancer, and suggests that circPTK2 may suppress cancer cell invasion and migration by inhibiting the maturation of miR-23a. The products from AnyGenes played a pivotal role in the research team’s discoveries. To read the full article, visit: PubMed Article.

AnyGenes® is mentioned in the article titled "CD147 Promotes Tumor Lymphangiogenesis in Melanoma via PROX-1," published on PubMed. This study examines the role of CD147, a transmembrane protein, in promoting tumor lymphangiogenesis in melanoma, a critical process in tumor progression. The research highlights how CD147 activates the expression of PROX-1, a key factor in the formation of lymphatic vessels, which in turn facilitates the spread of tumor cells through the lymphatic system. These findings open up new avenues for targeting lymphangiogenesis in melanoma treatment. The AnyGenes products used in this study were instrumental in these significant discoveries. To read the full article, visit: PubMed Article.

AnyGenes® was cited in this article exploring the role of EMMPRIN/CD147 in regulating urokinase-type plasminogen activator (uPA) and its implications in oral tumor progression. The study highlights the importance of this regulation in the tumor microenvironment and its influence on cell invasion and migration. AnyGenes products contributed to the molecular analyses conducted, providing key tools for these discoveries. To read the full article, visit: PubMed Article.

AnyGenes® is mentioned in the article titled "Determination of SARS-CoV-2 RNA in different particulate matter size fractions of outdoor air samples in Madrid during the lockdown." This study investigates the presence of SARS-CoV-2 in ambient air by analyzing samples of different particle sizes. The findings underscore the importance of air quality monitoring in relation to virus transmission. AnyGenes products contributed to the molecular analyses conducted, providing key tools for these discoveries. To read the full article, visit: PubMed Article.

AnyGenes® is mentioned in the article titled "Disruption of NIPBL/Scc2 in Cornelia de Lange Syndrome provokes cohesin genome-wide redistribution with an impact on the transcriptome." This study investigates the effects of NIPBL/Scc2 disruption on cohesin redistribution, highlighting its impact on gene expression. The findings provide valuable insights into the molecular mechanisms underlying this syndrome. AnyGenes products contributed to the molecular analyses conducted, providing key tools for these discoveries. To read the full article, visit: PubMed Article.

AnyGenes® is mentioned in the article titled "Microarray Analysis Revealed Inflammatory Transcriptomic Changes after LSL60101 Treatment in the 5XFAD Mouse Model." This study highlights the effects of LSL60101 treatment on transcriptomic inflammation in a mouse model of Alzheimer's disease. The findings provide interesting insights into the underlying mechanisms of this pathology. AnyGenes products contributed to the molecular analyses conducted, providing key tools for these discoveries. To read the full article, visit: PubMed Article.